Meridia sibutramine regulatory update

FDA's Endocrinologic and Metabolic Drugs Advisory Committee will meet on Sept. 15 to discuss cardiovascular safety signals seen in the long-term Phase III SCOUT trial of anti-obesity drug Meridia sibu...